Mid-term concerns weigh on SymBio after Japanese IPO
This article was originally published in Scrip
Executive Summary
Shares in newly listed SymBio Pharmaceuticals plunged by 34% on their first day of trading and had lost further ground by the end of last week, with investors apparently concerned over the Japanese venture's mid-term business prospects.